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Abstract 17 
Infertility is defined as failure to conceive after one year of unprotected intercourse. This 18 
dichotomisation into fertile versus infertile, based on lack of conception over 12 month period, is 19 
fundamentally flawed. Time to conception is strongly influenced by factors such as female age and 20 
whilst a minority of couples have absolute infertility (sterility), many are able to conceive without 21 
intervention but may take longer to do so, reflecting the degree of subfertility. This natural 22 
variability in time to conception means that subfertility reflects a prognosis rather than a diagnosis. 23 
Current clinical prediction models in fertility only provide individualised estimates of the probability 24 
of either treatment independent pregnancy or treatment dependent pregnancy, but do not take 25 
account of both.  Together, prognostic factors which are able to predict natural pregnancy and 26 
predictive factors of response to treatment would be required to estimate the absolute increase in 27 
pregnancy chances with treatment. This stratified medicine approach would be appropriate for 28 
facilitating personalised decision-making concerning whether or not to treat subfertile patients.  29 
Published models are thus far of little value for decisions regarding when to initiate treatment in 30 
patients who undergo a period of, ultimately unsuccessful, expectant management. We submit that 31 
a dynamic prediction approach, which estimates the change in subfertility prognosis over the course 32 
of follow-up, would be ideally suited to inform when the commencement of treatment would be 33 
most beneficial in those undergoing expectant management. Further research needs to be 34 
undertaken to identify treatment predictive factors and to identify or create databases to allow 35 
these approaches to be explored. In the interim, the most feasible approach is to use a combination 36 
of previously published clinical prediction models.  37 
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Introduction   38 
Infertility is defined as “a disease of the reproductive system defined by the failure to achieve a 39 
clinical pregnancy after 12 months or more of regular unprotected sexual intercourse” according to 40 
the World Health Organisation (WHO) and International Committee for Monitoring Assisted 41 
Reproductive Technology (ICMART) (Zegers-Hochschild et al., 2009). Absence of pregnancy within 42 
this time-period is interpreted as evidence of sterility by many couples, who then request immediate 43 
treatment. 44 
In fact, the probability of conceiving is highly variable (te Velde et al. 2000) and genuine unresolved 45 
infertility or sterility, occurs in a minority (3–5%) of all couples (Greenhall and Vessey 1990). 41TAs 46 
couples who are more “fertile”41T tend to conceive early, the length of time couples have been 47 
unsuccessful at conceiving reflects the degree of subfertility. The term “infertility” is often used 48 
interchangeably with “subfertility” ((Gnoth et al. 2005, Gurunath et al. 2011, Habbema et al. 2004)). 49 
However, in this article we define as subfertile those couples in whom routine investigations have 50 
not been able to identify any absolute barriers to conception such as blocked Fallopian tubes, 51 
anovulation or azoospermia. Many of these couples are advised to undergo a period of expectant 52 
management, meaning that they continue trying to conceive naturally for a specified period of time 53 
before being offered treatment. 54 
Data from non-contracepting populations (Bongaarts 1975) show that increase in the duration of 55 
unsuccessful unprotected intercourse is associated with decreasing chances of pregnancy. However, 56 
the definition of infertility as a failure to conceive within a year represents an oversimplification, as 57 
many couples in this group will conceive beyond one year (Bongaarts 1975, Snick et al. 1997). The 58 
only certain way of ‘diagnosing’ absolute infertility in subfertile couples, i.e. establishing with 59 
certainty that a couple is sterile, is lack of conception in women at the end of reproductive life. By 60 
then of course it is too late to rectify the situation by medical means. Thus, in order to be a clinically 61 
useful entity, subfertility needs to reflect the prognosis of a couple in terms of their ability to 62 
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conceive unaided. Such an approach recognises the fact that apart from duration, a woman’s ability 63 
to conceive also declines with her age and depends on many other factors that vary the chances of 64 
conception such as frequency of intercourse, semen quality and pelvic pathology (Evers 2002).  65 
Having acknowledged that subfertility represents a prognosis rather than an absolute diagnosis, it is 66 
worth considering the best way of assessing the chances of pregnancy for the purposes of initiating 67 
investigations and treatment. One option, which allows consideration of time on a continuous scale 68 
(rather than dichotomously) and a couple’s risk factors for conception, is to use appropriately 69 
developed and validated clinical prediction models. Many of these already exist in fertility and they 70 
either predict the chances of pregnancy following treatment or without treatment, but not both 71 
(Leushuis et al. 2009). However, a method of taking both groups into account to estimate the 72 
additional chances of pregnancy following treatment could allow clinicians to identify those who 73 
would benefit from it. For example, an absolute increase of 5% in the chance of pregnancy following 74 
in vitro fertilization (IVF) compared to no treatment, might be important to a woman aged 38 whose 75 
natural chances of pregnancy have declined with age, but not to a woman aged 28 whose natural 76 
chances are still relatively high. 77 
In this paper we describe the limitations of current clinical prediction models for subfertility and 78 
subsequently aim to explore the advancement of such models to address two key questions in 79 
fertility care: firstly, how should clinicians discriminate between those who need active fertility 80 
treatment versus those who do not? Secondly, given that subfertility prognosis changes over time, 81 
when should those on expectant management be offered active treatment? 82 
 83 
Existing clinical prediction models in subfertility 84 
Critical for the management of a subfertile couple prior to initiation of treatment is knowledge of 85 
their subfertility prognosis i.e. chances of spontaneous conception. As mentioned earlier, a way of 86 
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estimating subfertility prognosis is through clinical prediction modelling. A time-to-event statistical 87 
model (such as the Cox proportional hazards model) is a good method of predicting the chances of a 88 
binary outcome, such as conception (versus no conception), over a period of time. Such models 89 
adjust for prognostic factors, which are clinical or biological characteristics (such as female age and 90 
duration of infertility) that are associated with a clinical outcome (such as spontaneous pregnancy) 91 
in an untreated patient (Italiano 2011). Prognostic factors for subfertility can be obtained from the 92 
medical literature, clinical opinion or further research. Table 1 contains a list of known prognostic 93 
factors of spontaneous pregnancy from published models (Leushuis et al. 2009). The recently 94 
published Prognosis Research Strategy (PROGRESS) articles specify a framework of four interlinked 95 
themes for prognostic research. They recommend that large, prospective, registered prognostic 96 
factor studies with appropriate sample size and statistical analyses are required in order to find new 97 
prognostic factors that can predict an outcome (Hemingway et al. 2013, Hingorani et al. 2013, Riley 98 
et al. 2013, Steyerberg et al. 2013). 99 
A systematic review of clinical prediction models in reproductive medicine identified 29 prediction 100 
models that predicted spontaneous pregnancy (n=9) or successful intrauterine insemination (IUI, 101 
n=3) or IVF  n=17) (Leushuis et al. 2009). Of these 29 models, only eight were externally validated, 102 
three of which showed adequate performance (Custers et al. 2007, Hunault et al. 2004, Smeenk et 103 
al. 2000, Steures et al. 2006, Steures et al. 2004, Templeton et al. 1996, van der Steeg et al. 2007). 104 
Assessment of the predictive ability and external validation of a prediction model is essential if it is 105 
to be used to facilitate clinical practice (Collins 2005, Coppus et al. 2009). Aspects to evaluate include 106 
discrimination (how good a model is distinguishing between patients who do and do not become 107 
pregnant) and calibration (agreement between the probability estimate from the prediction model 108 
and observed outcome frequencies) (Steyerberg 2009). 109 
The Hunault model, synthesised from three previous models based on three prospective databases 110 
of subfertile women attending a Dutch University hospital, a Dutch general hospital and eleven 111 
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Canadian University Hospitals, was found to predict spontaneous pregnancy leading to live birth 112 
reasonably well (Hunault et al. 2004). It had poor discriminatory ability, which is generally the case 113 
with prediction modelling in subfertile couples who tend to be rather homogeneous in terms of 114 
clinical characteristics (Coppus et al. 2009), but calibrated well when applied to external cohorts 115 
(Hunault et al. 2005, van der Steeg et al. 2007). 116 
Two other models, which showed acceptable performance in the Leushuis et al (2009) review, were 117 
the Steures et al (2006) model which predicts live birth following IUI, and the Templeton et al (1996) 118 
model which predicts live birth following IVF. Both of these models also had poor discriminatory 119 
ability (Coppus et al. 2009, Smeenk et al. 2007). However, the Templeton model performs 120 
reasonably well after adjusting for improved IVF success rates over time (te Velde et al. 2014). Since 121 
the Leushuis review, a model developed using the Human Fertilisation and Embryological Authority 122 
(HFEA) database of all IVF treatments in the UK has been published (Nelson and Lawlor 2011) but 123 
performed no better than the Templeton model (te Velde et al. 2014). 124 
A prognostic model could be used to make risk-based decisions in clinical practice. This would 125 
involve calculating the absolute chance of spontaneous pregnancy occurring within a pre-specified 126 
time period, e.g. one year, for a given individual (see Figure 1, Model 1a). Decisions regarding 127 
whether or not to treat can then be made using some pre-specified clinically agreed chance cut-off. 128 
For example, the creators of the Hunault model considered couples with <20% chance of 129 
spontaneous pregnancy as a poor prognosis group who should undergo immediate treatment 130 
(Hunault et al. 2004). Those with >40% chance were labelled as having a high chance of spontaneous 131 
pregnancy and the article suggested that these couples should be encouraged to wait for another 132 
year. Those in the middle group of 20–40% chance should be advised in such a manner as to balance 133 
the probability of pregnancy against the risks from fertility treatment. 134 
However, using probabilities from a model that predicts treatment independent pregnancy to make 135 
treatment decisions does not take into account the chance that treatment may not be effective in 136 
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particular women. For example, being led solely by the above model cut-offs, a woman with a 15% 137 
chance of pregnancy would undergo immediate treatment. However, depending on the woman’s 138 
specific characteristics, her chance of pregnancy following treatment may be no greater, or, it may 139 
be substantially greater. Conversely, models that predict pregnancy following treatment do not tell 140 
us whether the woman’s absolute chance of pregnancy would have been any lower without 141 
treatment, and indeed how much lower (Figure 1, Model 1b). The best option would be to use a 142 
combined dataset, ideally from randomized controlled trial (RCT) data, including these two groups of 143 
women in order to model the additional benefit of treatment over no treatment. This can be made 144 
possible using a stratified medicine approach. 145 
 146 
Absolute versus relative risk 147 
Before we consider stratified medicine it is important to define absolute and relative risk.  Absolute 148 
risk refers to the chance that a patient will have some outcome of interest (for example, a treated 149 
patient has a 10% risk of mortality and a control patient has a 12.5% risk of mortality). The relative 150 
risk refers to the chance of the outcome for one group of patients compared with another (in the 151 
given example the relative risk of mortality decreases by 20% for the treatment group compared to 152 
the control group). The word ‘risk’ is used since the outcome is often unfavourable. However, since 153 
pregnancy is a favourable outcome the term ‘risk’ is generally replaced with ‘chance’. If the relative 154 
effect of treatment is constant for all patients, then the absolute benefit of treatment only increases 155 
in relation to the baseline pregnancy chances. For example, if statins have a constant relative risk 156 
reduction for all, then the absolute benefit is highest for those at highest risk of cardiovascular 157 
disease (LaRosa et al., 1999). 158 
 159 
To treat or not to treat? - A stratified medicine approach 160 
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Stratified medicine has been defined as ‘the targeting of treatments (including pharmaceutical and 161 
non-pharmaceutical interventions) according to the biological or risk characteristics shared by 162 
subgroups of patients’ (Hingorani et al. 2013). A clinician will use such an approach where the 163 
relative effect of treatment is believed to be inconsistent across patients. This means one or more 164 
patient characteristics are associated with changes in the relative effect of treatment. Such 165 
characteristics are called predictive factors of treatment response (Hingorani et al. 2013). The 166 
stratified medicine approach allows targeting of therapy based on the combination of subfertility 167 
prognostic factors and such treatment predictive factors, which increase the response to treatment 168 
in relation to no treatment. This enables decisions to be made regarding who should receive such 169 
treatment. For example, in non-small cell lung cancer, the response of the disease to chemotherapy 170 
is quite poor but there are therapy agents, gefitinib and erlotinib, which optimise therapy by being 171 
effective only in patients whose tumours harbour specific epidermal growth factor receptor profiles 172 
(Hall 2013). 173 
In the stratified medicine approach the relative effect of treatment is allowed to vary across patients 174 
according to their treatment predictive factors. The relative increase in pregnancy chances for 175 
treatment in relation to no treatment has limited value since it does not tell us from what baseline 176 
chance (i.e. chance of pregnancy without treatment) the increase occurs. Stratified medicine 177 
considers the absolute rather than the relative increase in chance of pregnancy with treatment since 178 
the former provides the more relevant individualised prediction of successful treatment to guide 179 
decision-making. 180 
Some thought needs to be given to identifying factors that predict differential treatment response. 181 
In fertility, the success of treatment, such as IVF, is heavily influenced by factors such as female age 182 
(van Loendersloot et al. 2010). As age is also a subfertility prognostic factor, increasing age may vary 183 
the additional effect of treatment over expectant management on chances of pregnancy. In other 184 
words, prognostic factors such as age, which affect the chance of spontaneous pregnancy and 185 
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success of IVF may also be treatment predictive factors which determine the relative effectiveness of 186 
treatment (Hingorani et al. 2013). Of interest is the difference in these two relative effects. 187 
Moreover, it is likely that an older woman whose chance of pregnancy with treatment is expected to 188 
be better than without, will require a more rapid resolution involving assisted reproduction, whilst a 189 
younger patient has sufficient time to undergo a series of less invasive (and cheaper) alternatives 190 
first. We know that as female age increases the ability of assisted reproduction technology to make 191 
up for all births lost by the natural decline of fertility decreases (Leridon 2004). Nevertheless, the 192 
absolute (and relative) benefit of treatment may be larger in older women than for younger women.  193 
There may also exist factors that are not necessarily prognostic that may predict the treatment 194 
response. For example, in women with different tubal factor subfertility problems those with 195 
hydrosalpinges had a poorer IVF pregnancy rate, which can be improved by salpingectomy (Johnson 196 
et al. 2011). Within such a cohort of women, subfertility prognosis would not be expected to vary 197 
between different tubal factor diagnoses, but type of tubal factor subfertility is clearly a treatment 198 
predictive factor. 199 
 200 
Issues to consider for a stratified approach 201 
A stratified model can be developed from: i. one data source that has compared treated versus 202 
untreated patient outcomes; or ii. two separate sources – one to model subfertility prognosis and 203 
one to predict outcome following treatment. We will discuss these in turn. 204 
One data source, one model 205 
This involves using one dataset, preferably from an RCT, comparing treatment with no treatment. 206 
One can then examine the effect of prognostic factors for subfertility (main effects in a statistical 207 
model) (Figure 1, Model 2a) together with treatment predictive factors (interaction terms in a 208 
statistical model) (Figure 1, Model 2b). 209 
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We could not find any examples of a published stratified medicine analysis for fertility using 210 
treatment predictive factors. However, a recent study attempted the secondary analysis of 211 
individual patient data from RCTs to determine whether a patient’s prognostic profile, based on a 212 
score from the Hunault model, influenced the effectiveness of different fertility treatments (van den 213 
Boogaard et al. 2013). Investigating how the prognostic score from a model affects the treatment 214 
response, rather than the individual treatment predictive factors which made up the score, is called 215 
a risk-stratified analysis (Kent DM 2007). 216 
Due to heterogeneity in the treatment protocols of the included trials in the Van den Boogaard study 217 
it was not possible to combine the individual patient data from each trial to conduct a meta-analysis. 218 
The modelling was performed in each trial separately. The study found no effect of prognostic 219 
profile on the effectiveness of different clinical strategies, including expectant management. This 220 
highlights the need for large RCTs with more heterogeneity in patient characteristics if they are to be 221 
used for secondary analyses involving modelling (Farooq et al. 2013). However, this is an expensive, 222 
challenging and lengthy process. 223 
Although large RCTs are the preference for stratified medicine research, the use of observational 224 
data containing treated and non-treated women is an alternative. Such data usually contain a larger 225 
and more varied sample of patients than an RCT. An observational design requires high quality 226 
electronic healthcare data that can be record-linked in order to obtain an accurate history of the 227 
patient’s journey (Hemingway et al., 2013). However, observational data can suffer from serious 228 
selection bias issues, and whilst there are methods available that may be able to account for some of 229 
these, the results of any analyses should be interpreted with caution. 230 
 231 
Two separate data sources, two models 232 
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In the absence of RCTs or observational databases containing both treated and non-treated women, 233 
a third approach is possible. This can use either previously published models – e.g. a prognostic 234 
model for spontaneous pregnancy, such as Hunault, and a model predicting treatment dependent 235 
pregnancy, such as the Nelson and Lawlor IVF model – or develop new models for each outcome 236 
using two separate data sources. The advantage of the former method is that most of the work has 237 
already been done and it is much less expensive than setting up a prospective, or even a 238 
retrospective, database from scratch. The difference in the absolute probability of success from both 239 
models would give the absolute benefit of treatment (Figure 1, Models 1a and 1b combined). 240 
However, a key problem with this method is the comparability of cohorts. The limitations of 241 
combining models developed from two different cohorts were highlighted in the recently updated 242 
National Institute of Clinical Excellence (NICE) clinical guideline on assessment and treatment for 243 
people with fertility problems (National Collaborating Centre for Women's and Children's Health 244 
2013). A health economic analysis to compare the cost-effectiveness of different treatment 245 
strategies over a woman’s reproductive life used the Hunault and the Nelson and Lawlor models to 246 
inform the cost-effectiveness model with probabilities of cumulative live birth in women following 247 
spontaneous pregnancy and IVF dependent pregnancy respectively. However, as the guideline 248 
acknowledges, there were major limitations associated with this approach. For example, the Hunault 249 
model was developed using a cohort of subfertile women, which excluded those who would not be 250 
expected to conceive naturally, meaning the severity of subfertility may not be as high as that in 251 
women referred for IVF (the cohort used for the Nelson and Lawlor models). Further, the maximum 252 
age of women used to develop the Hunault model was less than the maximum age included in the 253 
NICE cost-effectiveness model, which may result in an overestimate of the probability of 254 
spontaneous live birth in older aged women. However, if separate cohorts exist, which contain 255 
patients with very similar characteristics, who undergo either expectant management or treatment, 256 
then previous models can be adapted to fit such data or new models can be developed. If such 257 
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cohorts are available then this two-model approach would be equivalent to using the one model 258 
approach with statistical interaction terms between treatment and the treatment predictive factors. 259 
 260 
When to treat? – A dynamic prediction approach 261 
Another major aspect of clinical decision-making concerns the length of time couples should be 262 
advised to continue trying to conceive naturally before treatment should be offered. In order to do 263 
this we need a dynamic approach where we constantly assess the change in subfertility prognosis at 264 
different points in the future. One method is dynamic prediction modelling (van Houwelingen and 265 
Putter 2012). This involves fitting multiple time to event models from sequential equally spaced time 266 
points to predict natural pregnancy over, say, the following year (see Figure 2). This process enables 267 
one to determine the impact of delayed treatment on the predicted probability of pregnancy at 268 
different points in time. This is not the same as using, for example the Hunault model, to obtain the 269 
updated chances of pregnancy as time goes on by iteratively updating the same woman’s prognostic 270 
factors for subfertility at baseline (i.e. when the cause of infertility is established). Rather, as time 271 
progresses the more fertile couples are excluded from the cohort due to pregnancy.  Therefore 272 
after, for example, 6 months the cohort has reduced in size and is less fertile on average than the full 273 
sized cohort on which the model was originally based.  Furthermore, since the original follow-up 274 
period has been extended by 6 months (i.e. follow-up now ends 18 months from baseline as 275 
opposed to 12 months) some of the women may have conceived during this period. Thus, different 276 
model estimates will be obtained. 277 
Dynamic prediction could be used to advise those patients who are found to have a high chance of 278 
conceiving spontaneously at their first visit on when to return for treatment if their attempts are 279 
unsuccessful e.g. when their absolute chance of pregnancy dips below some pre-specified threshold. 280 
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It could also be used to make decisions regarding the immediate treatment for couples who have a 281 
low probability of pregnancy at their initial visit, which will decline further with each passing month. 282 
Dynamic prediction should be used with the stratified medicine approach in order to estimate the 283 
change in the absolute benefit of treatment over time. In a couple with a good subfertility prognosis 284 
initially advised expectant management, this approach could be used to decide when in the future 285 
the absolute benefit of treatment is likely to trump their chance of spontaneous pregnancy such that 286 
the couple should be advised to return for treatment. 287 
Dynamic prediction requires a cohort of patients with a sufficient length of follow-up to enable 288 
modelling at different time points. For this reason, existing observational datasets would be more 289 
suitable than an RCT. Finally, as for all clinical prediction modelling, the key steps involved in 290 
development and validation should be considered. The latter have been highlighted in the 291 
PROGRESS series (Steyerberg et al. 2013). 292 
 293 
Practical recommendations 294 
Given the complexities of the above approach to individualised-decision making in subfertility 295 
treatment, it is worth considering some practical guidelines for clinical practice and research. Firstly, 296 
the decision whether to treat a subfertile patient requires careful consideration of her background 297 
chance of spontaneous pregnancy and her predicted response to treatment. The former is 298 
influenced by prognostic factors and the latter by treatment predictive factors. Currently, in the 299 
Netherlands, an online prediction tool called ‘Freya’, based on the Hunault model, is used in clinical 300 
practice to make treatment decisions based on the probability of spontaneous ongoing pregnancy 301 
within the next 12 months (Hunault et al. 2004). However, clinicians should be aware that this model 302 
does not provide an estimate of response to treatment. Currently, the only way to do this is to use a 303 
combination of existing models from the literature, such as the Hunault model and the Nelson and 304 
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Lawlor model, which can be used to predict the chance of live birth following IVF. As mentioned 305 
earlier, this approach was used in a cost-effectiveness analysis of IVF relative to expectant 306 
management by NICE who acknowledge the shortcomings of this approach (National Collaborating 307 
Centre for Women's and Children's Health 2013). 308 
 309 
Secondly, clinicians looking after couples with unexplained subfertility need to make a conscious 310 
decision as to when treatment should be offered. Depending on patient characteristics, such as 311 
female age, the live birth rate following one or more episodes of treatment will vary compared to 312 
what might be expected without treatment. Thus, it may be better to treat some women straight 313 
away after a diagnosis has been made, whilst in others a period of expectant management may lead 314 
to comparable or better live birth rates without the expense and invasiveness of active treatment. 315 
From the NICE analysis using the combined models, a 34 year old woman with two years of 316 
unexplained infertility is predicted to have a treatment independent live birth rate of 20% (National 317 
Collaborating Centre for Women's and Children's Health 2013) compared to 40% after one cycle of 318 
IVF. The same model predicts a live birth rate of 55% without treatment versus 70% following three 319 
complete cycles of IVF over the next 11 years, suggesting that it would seem advantageous to offer 320 
IVF treatment. 321 
Finally, output from clinical predictive models need to be interpreted in the context of the individual 322 
circumstances of each couple. For fertility care to be genuinely patient centred, treatment decisions 323 
should involve couples themselves and accommodate their personal values and preferences (Dancet 324 
et al. 2011). 325 
 326 
Conclusions 327 
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The current one-year definition of infertility should be used as a trigger for referral to the fertility 328 
clinic in order to initiate investigations and estimate prognosis – but not necessarily to begin 329 
treatment in all. 330 
Current prognostic models in reproductive medicine are reasonably good at predicting the chances 331 
of pregnancy in either women who are treated or those who are not. As none of the existing models 332 
include both groups, predicting the marginal benefit of treatment versus no treatment is less 333 
accurate. 334 
We advise the stratified medicine approach to identify those who actually benefit more from fertility 335 
treatment based on their prognostic and treatment predictive factors. Subsequently, the added 336 
benefit of treatment needs to be considered in context, for example in relation to the age of the 337 
woman. We also advise the dynamic prediction approach to estimate the patient’s changing 338 
subfertility prognosis over time which could inform the decision about when to treat. 339 
Further research needs to be undertaken to identify treatment predictive factors and to identify or 340 
create databases to allow these approaches to be explored. RCT data are preferred, but are the most 341 
challenging and expensive choice. In the interim, the most feasible option is to use output from a 342 
combination of previously published clinical prediction models, whilst acknowledging the specific 343 
clinical circumstances of each couple and their preferences. 344 
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Table 1. Prognostic factors used to predict spontaneous pregnancy (taken from Leushuis et al, 2009). 475 
Couple factors 
 Duration of subfertility (year) 
 Secondary subfertility 
Female factors 
 Female age (years) 
 Referral status (tertiary care) 
 Ovulation disorder 
 Pelvic surgery 
 Tubal defect 
 Endometriosis 
 Ovulation or cervical disorder 
 Uterine abnormality (UA) 
 UA and ovulation or cervical disorder 
Male factors 
 Male age (year) 
 Sperm motility (%) 
 Degree of motility (good) 
 Sperm morphology (%) 
 Sperm concentration (x 10P6P) 
 Abnormal post coital test (PCT) 
 World Health Organisation (WHO) semen defect 
 Hypo-osmotic test (HOS) test (%) 
 Urethritis in history 
 Fertility problem in male’s family 
 476 
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Figure 1 Diagram to explain absolute and relative benefit of treatment (Tx) in the stratified medicine 477 
approach for individualised predictions of a pregnancy outcome, such as live birth, in a subfertile 478 
population 479 
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Figure 2 Dynamic prediction for pregnancy prognosis 499 
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Model 1: A time to event model predicts the probability of pregnancy (PR0R) within one year at the point where the type of 524 
infertility is established (baseline).   525 
Model 2: A second time to event model predicts the probability of pregnancy (PR1R) within one year from 1 month after 526 
baseline.  All women who were pregnant in the first month (dotted line) are excluded. 527 
This is repeated from every month thereafter, until month N. 528 
Model N+1: An (N+1)th time to event model predicts the probability of pregnancy (PRNR) within one year from N months 529 
after baseline.  All women who were pregnant up to month N (dotted line) are excluded. 530 
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